Robert E. Waltermire - 24 Feb 2022 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Senior VP, Chief Pharma Dev.
Signature
/s/ Brian J. Lynch, As attorney-in-fact for Reporting Person
Issuer symbol
MDGL
Transactions as of
24 Feb 2022
Net transactions value
$0
Form type
4
Filing time
24 Feb 2022, 19:17:26 UTC
Previous filing
04 Aug 2021
Next filing
18 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Call Option Award $0 +12,250 $0.000000 12,250 24 Feb 2022 Common Stock 12,250 $87.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the shares on the first anniversary of the date of grant (02/24/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.